SO:
http://www.virtualtrials.com/Tam1.cfmTI:
Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen AU: William T. Couldwell, David R. Hinton, Amy A. Surnock, Christopher M. DeGiorgio, Leslie P. Weiner, Michael L.J. Apuzzo, Lena Masri, Ronald E. Law and Martin H. Weiss
From the Departments of Neurological Surgery [WTC, DRH, AAS, CMD, MLJA, REL, MHW], Neurology [CMD, LPW], Pathology [DRH], and Preventative Medicine, Division of Biometry [LM], University of Southern California School of Medicine, Los Angeles, California
Abstract (= Zitat)
The present clinical trial was undertaken to assess the clinical safety and possible efficacy of administering tamoxifen to patients with recurrent malignant glial tumors at dosages calculated to achieve levels sufficient to inhibit protein kinase C within the tumor cells. Chronic oral tamoxifen was administered in very high dosages to 32 patients (20 males:12 females, age range 26-75, mean 49 years) with histologically verified malignant glioma [anaplastic astrocytoma (AA; 12 patients) or glioblastoma multiforme (GBM; 20 patients)], who had demonstrated clinical and radiographic progression or recurrence following external beam radiation therapy (and additional chemotherapy in 11; immunotherapy in 2). The dosage of tamoxifen administered was 200 mg/day to males and 160 mg/day to females given in a b.i.d. schedule. Clinical and radiographic (defined as a greater than 50% decrease in volume of the enhancing lesion volume on MRI and a decrease in metabolic activity on serial positron emission tomographic (PET) scans) response was noted in 8 patients (25%; 4/12 with AA and 4/20 GBM), with an additional 6 patients (19%) exhibiting stabilization of disease with minimal side effects. Median survival from the time of diagnosis for the entire cohort was 24 months (104 weeks), anaplastic astrocytoma group 42.5 months (185 weeks), and glioblastoma group 17.4 months (75.5 weeks). From the initiation of tamoxifen, median survival for the entire cohort was 10.1 months (44 weeks), anaplastic astrocytoma group 16 months (69 weeks), and glioblastoma group 7.2 months (31 weeks). The mean length of followup of all patients after initiating tamoxifen was 16 months (69 weeks), while the mean length of followup of alive patients is 22.6 months (98 weeks) (range up to 51 months). These data suggest that a subgroup of patients with malignant gliomas respond or stabilize with chronic high-dose tamoxifen therapy. This therapy may represent an alternative or adjuvant to existing chemotherapies for these tumors; further clinical trials are warranted.
Man kann den Artikel ganz lesen. Oben auf den Link klicken. Bei SO = source = Quelle.
